Journal of Psychoactive Drugs · 2017 · 21 citations · 22 references
NursingHealth PolicyPharmaceutical PolicyBehavioral HealthHealth InsuranceSubstance Use DisordersOpioid AnalgesicsOpioid PolicyOpioid TherapyOpioid Use DisorderPharmacy Benefit ManagementPrescription Drug CoverageExpanded Access UseIndividual Health Insurance PlansOpioid Use Disorder Treatment AccessPharmacy Benefit ArrangementsPrior Authorization RegulationSubstance Use Disorder CoverageSubstance Use Disorder Treatment AccessSupplemental Health Insurance Plans
Opioid use disorders (OUDs) are receiving significant attention in the U.S. as a public health crisis. Access to treatment for OUDs is essential and was expected to improve following implementation of the federal parity law and the Affordable Care Act. This study examines changes in coverage and management of treatments for OUDs (opioid treatment programs (OTPs) as a covered service benefit, buprenorphine as a pharmacy benefit) before, during, and after parity and ACA implementation. Data are from three rounds of a nationally representative survey conducted with commercial health plans regarding behavioral health services in benefit years 2003, 2010, and 2014. Data were weighted to be representative of health plans' commercial products in the continental United States (2003 weighted N = 7,469, 83% response rate; 2010 N = 8,431, 89% response rate; and 2014 N = 6,974, 80% response rate). Results showed treatment for OUDs was covered by nearly all health plan products in each year of the survey, but the types and patterns varied by year. Prior authorization requirements for OTPs have decreased over time. Despite the promise of expanded access to OUD treatment suggested by parity and the ACA, improved health plan coverage for treatment of OUDs, while essential, is not sufficient to address the opioid crisis.
22
Kirsten Beronio, Sherry Glied, Richard G. Frank · The Journal of Behavioral Health Services & Research · 2014 · 191 citations